Real-World experience of interictal burden and treatment in migraine: a qualitative interview study

被引:16
|
作者
Lo, Siu Hing [1 ]
Gallop, Katy [1 ]
Smith, Timothy [2 ]
Powell, Lauren [3 ]
Johnston, Karissa [3 ]
Hubig, Lena T. [1 ]
Williams, Emma [1 ]
Coric, Vladimir [4 ]
Harris, Linda [4 ]
L'Italien, Gilbert [4 ]
Lloyd, Andrew J. [1 ]
机构
[1] Acaster Lloyd Consulting Ltd, 8th Floor,Lacon House,84Theobalds Rd, London WC1X 8NL, England
[2] StudyMetrix Res LLC, 3862 Mexico Rd, St Peters, MO 63303 USA
[3] Broadst HEOR, 201-343 Railway St, Vancouver, BC V6A 1A4, Canada
[4] Biohaven Pharmaceut Inc, 215 Church St, New Haven, CT 06510 USA
来源
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / 01期
关键词
Migraine; Interictal burden; Health-related quality of life; Treatment experience; Qualitative;
D O I
10.1186/s10194-022-01429-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on patients' health-related quality of life (HRQL). Acute and preventive treatments may lift the burden of the disease, but they often have unwanted side effects and limited effectiveness. The objective of this study was to understand the interictal burden of migraines, from the patient perspective, and to explore patient experience with migraine treatments. Methods Participants (n=35) with a self-reported diagnosis of migraine were recruited in the US, UK and Canada, including a subgroup of patients who had taken calcitonin gene-related peptide monoclonal antibody (CGRP mAb) treatment for at least three months. Participants completed a background questionnaire, followed by a semi-structured interview via telephone or video call. The interviews explored patients' migraine symptoms, perception of interictal burden and treatment experience. The interview transcripts were analysed using thematic analysis. Results The most reported migraine symptom was migraine pain, followed by aura, sensory sensitivity and nausea. Most participants reported interictal impact on HRQL, lifestyle changes they made to avoid triggers or in anticipation of an attack, impacts on work, career, daily activities and relationships. Emotional impacts were reported by all participants, including anger, depression, anxiety and hopelessness. Many participants who took preventive treatments reported improvements in HRQL and functioning but still experienced breakthrough attacks. Among patients who took CGRP mAbs, participants noted varying consistency of treatment effectiveness between treatment administrations. Conclusion This study detailed the additional HRQL impact of migraine in-between migraine attacks and described the unmet need for effective treatment options to prevent and mitigate migraine attacks.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
    Ja Bin Hong
    Kristin Sophie Lange
    Mira Fitzek
    Lucas Hendrik Overeem
    Paul Triller
    Anke Siebert
    Uwe Reuter
    Bianca Raffaelli
    The Journal of Headache and Pain, 24
  • [32] Real-world experience with netakimab in the treatment of spondyloarthritis
    Meshkov, Alexey D.
    Vorobyeva, Natalya M.
    Ostapenko, Valentina S.
    Pykhtina, Valentina S.
    Ruzanova, Viktoriya I.
    Perlova, Olesia A.
    Kordyukova, Irina S.
    Naumov, Anton, V
    Khovasova, Natalia O.
    Tkacheva, Olga N.
    TERAPEVTICHESKII ARKHIV, 2023, 95 (12) : 1172 - 1178
  • [33] INTERICTAL BURDEN OF MIGRAINE: CORRELATIONS WITH OTHER MEASURES OF MIGRAINE BURDEN AND EFFECTS OF GALCANEZUMAB MIGRAINE-PREVENTIVE TREATMENT
    Detke, Holland
    Buse, Dawn
    Ford, Janet
    Hand, Austin
    Jedynak, Jakub
    Lipton, Richard
    Port, Martha
    Sandoe, Claire
    CEPHALALGIA, 2020, 40 : 16 - 17
  • [34] Interictal Burden of Migraine: Correlations with Other Measures of Migraine Burden and Effects of Galcanezumab Migraine-Preventive Treatment
    Sandoe, Claire
    Lipton, Richard
    Buse, Dawn
    Ford, Janet
    Hand, Austin
    Jedynak, Jakub
    Port, Martha
    Detke, Holland
    NEUROLOGY, 2021, 96 (15)
  • [35] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Taoufik Alsaadi
    Suzan Noori
    Razmig Varakian
    Saly Youssef
    AbuBaker Almadani
    BMC Neurology, 22
  • [36] Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study
    Shantaily Lourens
    Laura Van Deun
    Ilse Peeters
    Koen Paemeleire
    Annelies Van Dycke
    Nina De Klippel
    Jean Schoenen
    Shannon Ritter
    Josefin Snellman
    Jan Versijpt
    Acta Neurologica Belgica, 2023, 123 : 1495 - 1503
  • [37] Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience
    Mahovic, Darija
    Bracic, Matea
    Jakus, Lukrecija
    Cvetkovic, Vlasta Vukovic
    Krpan, Marina
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 214
  • [38] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Alsaadi, Taoufik
    Noori, Suzan
    Varakian, Razmig
    Youssef, Saly
    Almadani, AbuBaker
    BMC NEUROLOGY, 2022, 22 (01)
  • [39] Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study
    Lourens, Shantaily
    Van Deun, Laura
    Peeters, Ilse
    Paemeleire, Koen
    Van Dycke, Annelies
    De Klippel, Nina
    Schoenen, Jean
    Ritter, Shannon
    Snellman, Josefin
    Versijpt, Jan
    ACTA NEUROLOGICA BELGICA, 2023, 123 (04) : 1495 - 1503
  • [40] TREATMENT PATTERNS IN MIGRAINE: A REAL-WORLD ANALYSIS IN A US POPULATION
    Lombard, L.
    Ford, J.
    Jackson, J.
    Milligan, G.
    Cotton, S.
    Ahl, J.
    CEPHALALGIA, 2016, 36 : 29 - 30